ADO
Akademische Projekte im prospektiven multizentrischen Hautkrebsregister ADOREG
First published: 22 November 2021
No abstract is available for this article.
Literatur
- 1Schaper-Gerhardt K, Okoye S, Herbst R et al. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. Eur J Cancer 2018; 88: 67–76.
- 2Livingstone E, Zaremba A, Horn S et al. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. Br J Dermatol 2020; 183: 928–939.
- 3Leiter U, Loquai C, Reinhardt L et al. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. J Immunother Cancer 2020; 8: e000897.
- 4Moritz RKC, Gutzmer R, Zimmer L et al. SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry. Eur J Cancer 2021; 144: 382–385.
- 5Koch EAT, Petzold A, Wessely A et al. Immune checkpoint blockade for metastatic uveal melanoma: patterns of response and survival according to the presence of hepatic and extrahepatic metastasis. Cancers 2021; 13: 3359.
- 6Stege H, Haist M, Schultheis M et al. Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma – a multicenter ADOReg study. Cancers 2021; 13: 2312.
